656827-13-3

Basic information

• Product Name: (R)-BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE
• Synonyms: (R)-BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE
• CAS NO: 656827-13-3
• Molecular Formula: C₁₆H₂₂N₂O₅
• Molecular Weight: 322.36
• Mol File: 656827-13-3.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE(656827-13-3)
• EPA Substance Registry System: (R)-BENZYL 4-(N-METHOXY-N-METHYLCARBAMOYL)-2,2-DIMETHYLOXAZOLIDINE-3-CARBOXYLATE(656827-13-3)

Safety Data

• Hazardous Substances Data: 656827-13-3(Hazardous Substances Data)

Upstream product

• 1092473-80-7 (R)-benzyl 3-hydroxy-1-(methoxy(methyl)amino)-1-oxopropane-2-ylcarbamate 
• 77-76-9 2,2-dimethoxy-propane 
• 501-53-1 benzyl chloroformate 
• 6081-61-4 N-(benzyloxycarbonyl)-D-serine 

Downstream Products

• 656827-14-4 1-[(4R)-3-N-benzyloxycarbonyl-2,2-dimethyl-1,3-oxazolidin-4-yl]-but-3-en-1-one 
• 870651-04-0 N-benzyloxycarbonyl-(4S)-2,2-dimethyl-4-(1'-oxo-4'-pentenyl)-1,3-oxazolidine 
• 870650-96-7 ((1R,2S)-2-Hydroxy-1-hydroxymethyl-hex-5-enyl)-carbamic acid benzyl ester 
• 870651-05-1 (R)-4-((S)-1-Hydroxy-pent-4-enyl)-2,2-dimethyl-oxazolidine-3-carboxylic acid benzyl ester 
• 870651-08-4 (2R,3S)-3-(tert-Butyl-dimethyl-silanyloxy)-2-hydroxymethyl-piperidine-1-carboxylic acid benzyl ester 
• 870651-09-5 (2S,3S)-N-tert-butoxycarbonyl-3-(tert-butyldimethylsilyloxy)pipecolic acid 
• 870651-07-3 3-(tert-butyl-dimethyl-silanyloxy)-2-(tert-butyl-dimethyl-silanyloxymethyl)-6-hydroxy-piperidine-1-carboxylic acid benzyl ester 
• 870651-06-2 (2R,3S)-2-(tert-butoxycarbonylamino)-1,3-bis(tert-butyldimethylsilyloxy)hept-6-ene 
• 824411-64-5 1-[(4R)-3-N-benzyloxycarbonyl-2,2-dimethyl-1,3-oxazolidin-4-yl]-but-2-en-1-one 
• 824411-67-8 (5S)-5-[(4R)-3-N-benzyloxycarbonyl-2,2-dimethyl-1,3-oxazolidin-4-yl]-2,5-dihydrofuran-2-one 
• 824411-63-4 (6S)-6-[(4R)-3-N-benzyloxycarbonyl-2,2-dimethyl-1,3-oxazolidin-4-yl]-5,6-dihydropyran-2-one 
• 824411-66-7 (4R)-4-[(1'S)-1-acryloyloxy-but-2-enyl]-3-N-benzyloxycarbonyl-2,2-dimethyl-1,3-oxazolidine 
• 824411-61-2 (4R)-4-[(1'S)-1-acryloyloxy-but-3-enyl]-3-N-benzyloxycarbonyl-2,2-dimethyl-1,3-oxazolidine 
• 824411-75-8 (R)-4-((2R,3S,4R)-3,4-Dihydroxy-5-oxo-tetrahydro-furan-2-yl)-2,2-dimethyl-oxazolidine-3-carboxylic acid benzyl ester 

Relevant articles and documents

Amipurimycin: Total Synthesis of the Proposed Structures and Diastereoisomers

The proposed diastereoisomers (1 a–d) together with their C8′-epimers (1 e–h) of amipurimycin, a unique antifungal peptidyl nucleoside antibiotic, have been synthesized for the first time. The synthetic approach is efficient and stereodivergent, and features a stereoselective aldol condensation to build the branched C9 sugar amino acid skeleton and a regio- and stereocontrolled gold(I)-catalyzed N-glycosylation to furnish the purine nucleoside. Analysis of the NMR data suggests that the previously assigned configuration of the tertiary C3′ in amipurimycin should be of opposite configuration.

METHOD OF TREATING POLYCYSTIC KIDNEY DISEASES WITH CERAMIDE DERIVATIVES

PROBLEM TO BE SOLVED: To provide a method of treating polycystic kidney diseases with ceramide derivatives. SOLUTION: A pharmaceutical composition for treating polycystic kidney disease in a subject comprises an effective amount of a predetermined compoun

Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease

A method of treating a glomerular disease selected from the group consisting of mesangial proliferative glomerulonephritis, collapsing glomerulopathy, proliferative lupus nephritis, crescentic glomerulonephritis and membranous nephropathy in a subject com

Polyhydroxylated pyrrolidine and 2-oxapyrrolizidine as glycosidase inhibitors

Using D-serine as a chiral precursor, a polyhydroxylated pyrrolidine (1), its derivatives bearing carboxylate, phosphate and phosphonate groups (2-4) and an oxapyrrolizidine (5) were synthesized. The pyrrolidine ring was formed by intramolecular amino-mercuration. The bicyclic scaffold of oxapyrrolizidine was further constructed by an intramolecular attack of the carbamate group on the iodomethyl group. Compounds 1 and 5 were found to inhibit β-glucosidase and α-galactosidase, respectively, in a competitive manner, whereas compounds 2, 3 and 4 did not produce significant inhibition against glycosidases. The Royal Society of Chemistry 2013.

2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE INHIBITORS

A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating